Eli Lilly & Co. (LLY) – Press Releases
-
Tirzepatide reduced sleep apnea severity by up to nearly two-thirds in adults with obstructive sleep apnea (OSA) and obesity
-
Lilly Confirms Date and Conference Call for First-Quarter 2024 Financial Results Announcement
-
More than two-thirds of people with atopic dermatitis and skin of color experienced skin improvement in a first-of-its-kind lebrikizumab study
-
U.S. Food and Drug Administration to Convene Advisory Committee Meeting to Discuss the TRAILBLAZER-ALZ 2 Study of Donanemab
-
Lilly's Newest Phase of Get Better Campaign Challenges Misperceptions About Obesity Care
-
Lilly Announces Details of Presentations at 2024 American Association for Cancer Research (AACR) Annual Meeting
-
Lilly to Participate in Cowen's 44th Annual Health Care Conference
-
Global Fibromyalgia Treatment Market Expected to Reach $4.6 billion by 2032
-
Philip Johnson to Retire as Lilly Treasurer
-
Lilly Reports Strong Fourth-Quarter 2023 Financial Results and Provides 2024 Guidance
-
Johna Norton to Retire as Lilly Executive Vice President of Global Quality
-
Positive Phase 1/2 Clinical Trial Data for an Investigational Gene Therapy for Genetic Hearing Loss to be Presented at the Association for Research in Otolaryngology 2024 MidWinter Meeting
-
Lilly Confirms Date and Conference Call for Fourth-Quarter 2023 Financial Results and 2024 Financial Guidance
-
Henlius and Sermonix Announce Strategic Collaboration and Exclusive License Agreements for Novel Endocrine Therapy Lasofoxifene
-
Lilly Launches End-to-End Digital Healthcare Experience through LillyDirect™
-
Lilly to Participate in J.P. Morgan Healthcare Conference
-
Lilly Completes Acquisition of POINT Biopharma
-
Lilly Extends Tender Offer to Acquire POINT Biopharma to Dec. 22, 2023
-
Updated Data from the BRUIN Phase 1/2 Study of Pirtobrutinib in Chronic Lymphocytic Leukemia and Mantle Cell Lymphoma Presented at the 2023 ASH Annual Meeting
-
Lilly's Zepbound™ (tirzepatide) achieved additional 6.7% weight loss following a 36-week open-label lead-in period, for a total mean weight loss of 26.0% from study entry over 88 weeks
-
Lilly Announces 15% Dividend Increase, First-Quarter 2024 Dividend
-
Lilly to Present Final Overall Survival Analysis from the MONARCH 3 Study of Verzenio® (abemaciclib) and Additional Results from Its Breast Cancer Portfolio at the 2023 San Antonio Breast Cancer Symp
-
Zepbound™ (tirzepatide) is Now Available in U.S. Pharmacies for Adults Living with Obesity
-
Lilly Extends Tender Offer to Acquire POINT Biopharma to Dec. 15, 2023
-
Jaypirca® (pirtobrutinib) Now Approved by U.S. FDA for the Treatment of Adult Patients with Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Who Have Received at Least Two Lines of Therapy,
-
Lilly Announces Plans to Open its First-ever Gateway Labs Site in San Diego
-
Alexandria Real Estate Equities, Inc. Announces Exclusive Partnership With Lilly to Expand Lilly Gateway Labs to San Diego
-
Lilly to expand injectable manufacturing capacity with planned $2.5 billion site in Germany
-
Lilly Extends Tender Offer to Acquire POINT Biopharma to Dec. 1, 2023
-
Lilly Announces the Receipt of NRC Consent in Connection with its Proposed Acquisition of POINT Biopharma
-
Lilly to Participate in Evercore ISI HealthCONx Conference
-
POINT Biopharma Reports Third Quarter 2023 Financial Results and Provides Business Highlights
-
Lilly Announces Extension of Tender Offer to Acquire POINT Biopharma
-
FDA Approves Lilly's Zepbound™ (tirzepatide) for Chronic Weight Management, a Powerful New Option for the Treatment of Obesity or Overweight with Weight-Related Medical Problems
-
OrsoBio Announces $60M Series A Financing to Advance Metabolic Portfolio for the Treatment of Obesity and Associated Disorders
-
Lilly Announces Details of Pirtobrutinib Presentations in B-Cell Malignancies at 2023 ASH Annual Meeting
-
Lilly Reports Third-Quarter 2023 Financial Results, Highlights Strong Sales Growth and Business Development Activity
-
Hip-Hop Classic "It Takes Two" Takes on New Meaning in Remix to Elevate Importance of Testing for Kidney Disease
-
Lilly Declares Fourth-Quarter 2023 Dividend
-
FDA Approves Lilly's Omvoh™ (mirikizumab-mrkz), A First-in-Class Treatment for Adults with Moderately to Severely Active Ulcerative Colitis
-
Lilly to Participate in UBS Biopharma Conference 2023
-
Lilly's Retevmo® (selpercatinib) Phase 3 Results in RET Fusion-Positive Non-Small Cell Lung Cancer and RET-Mutant Medullary Thyroid Cancer Both Published in The New England Journal of Medicine and Pr
-
Lilly Confirms Date and Conference Call for Third-Quarter 2023 Financial Results Announcement
-
Landmark 5-Year monarchE Outcome Data Demonstrate Verzenio® (abemaciclib)'s Long-Term Impact on Cancer Recurrence in High-Risk Early Breast Cancer
-
Nearly 80% of patients with moderate-to-severe atopic dermatitis maintained clear or almost clear skin with Lilly's lebrikizumab monthly maintenance dosing at two years
-
Lilly's tirzepatide shows additional 21.1% weight loss after 12 weeks of intensive lifestyle intervention, for a total mean weight loss of 26.6% from study entry over 84 weeks
-
Lilly's Mirikizumab Helped Patients with Crohn's Disease Achieve Long-Term Remission in Phase 3 Trial
-
Lilly Announces Details of Presentations at ESMO Congress 2023
-
Loxo@Lilly Unveils Three New Oncology Programs at 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
-
Lilly Announces Leadership Transitions
Back to LLY Stock Lookup
